Share on StockTwits

Zeltiq Aesthetics (NASDAQ:ZLTQ) CEO Mark J. Foley sold 7,123 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $19.57, for a total transaction of $139,397.11. Following the sale, the chief executive officer now directly owns 658,481 shares in the company, valued at approximately $12,886,473. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ZLTQ has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Zeltiq Aesthetics from $26.00 to $27.00 in a research note on Thursday, July 31st. Analysts at Maxim Group raised their price target on shares of Zeltiq Aesthetics from $25.00 to $30.00 in a research note on Wednesday, July 30th. They now have a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Zeltiq Aesthetics currently has an average rating of “Buy” and an average target price of $25.00.

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) traded down 0.96% on Friday, hitting $19.56. 424,966 shares of the company’s stock traded hands. Zeltiq Aesthetics has a 52-week low of $6.75 and a 52-week high of $24.79. The stock has a 50-day moving average of $16.91 and a 200-day moving average of $17.66. The company’s market cap is $734.0 million.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.20. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $34.93 million. The company’s quarterly revenue was up 79.1% on a year-over-year basis. Analysts expect that Zeltiq Aesthetics will post $-0.18 EPS for the current fiscal year.

Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.